Bictegravir/emtricitabine/tenofovir-alafenamide/lenacapavirResistance and poor adherence.: case report

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-024-66078-x
中图分类号
学科分类号
摘要
引用
收藏
页码:96 / 96
相关论文
共 50 条
  • [41] Network meta-analysis of darunavir/cobicistat/emtricitabine/tenofovir-alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide in treatment-naive patients with HIV-1 infection
    Van Sanden, S.
    Schweikert, B.
    Moecklinghoff, C.
    Tronczynski, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [42] Hepatic safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
    Johnson, M.
    Taylor, S.
    Wei, X.
    Collins, S.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 40 - 40
  • [44] Bictegravir/emtricitabine/tenofovir alafenamide after virologic failure to cabotegravir/rilpivirine
    Giguere, Pierre
    Agtarap, Kyla
    McGuinty, Michaeline
    Touchie, Claire
    Kravcik, Steve
    Angel, Jonathan B.
    AIDS, 2025, 39 (06) : 777 - 779
  • [45] Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
    Tiraboschi, J.
    Prieto, P.
    Saumoy, M.
    Silva, A.
    Imaz, A.
    Scevola, S.
    Fernandez-Olivares, G.
    Navarro-Alcaraz, A.
    Piatti, C.
    Podzamczer, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 79 - 80
  • [48] Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
    Corona, Diana
    Perez-Valero, Ignacio
    Camacho, Angela
    Liarte, Angela Gutierrez
    Montero-Alonso, Marta
    Aleman, Maria Remedios
    Ruiz-Seco, Pilar
    Gonzalez, Alexandre Perez
    Riera, Melchor
    Jarrin, Inmaculada
    Rivero-Juarez, Antonio
    Rivero, Antonio
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (01)
  • [49] Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
    Emma D. Deeks
    Drugs, 2018, 78 : 1817 - 1828
  • [50] ECONOMIC AND ORGANIZATIONAL ADVANTAGES OF BICTEGRAVIR/ALAFENAMIDE TENOFOVIR/EMTRICITABINE FOR HIV TREATMENT
    Ferrario, L. B.
    Menzaghi, B.
    Rizzardini, G.
    Bellavia, D.
    Schettini, F.
    Garagiola, E.
    Foglia, E.
    VALUE IN HEALTH, 2024, 27 (12) : S96 - S96